Search
Zuclopenthixol
go.drugbank.com/drugs/DB01624ApprovedInvestigationalIt is known that zuclopenthixol is metabolized by Cytochrome P450 2D6. Zuclopenthixol was approved for use in Canada in 2011, but is not approved for use in the United States. … These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromePatent Blue
go.drugbank.com/drugs/DB13967ApprovedInvestigationalPatent blue was developed by Guerbet and approved by Health Canada on December 31, 1979.[L1113] The isomer isosulphan is used in the United States for the same indications than patent blue.[A32574]
Adalimumab
go.drugbank.com/drugs/DB00051ApprovedInvestigational[A39983] Several biosimilars to adalimumab. Adalimumab-atto was the first adalimumab biosimilar approved by the FDA in 2016.[L44953] Adalimumab-adaz was approved by the FDA on October 31, 2018. … A high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm), a biosimilar to Humira®, was approved by the FDA in May 2024 for the treatment of multiple chronic inflammatory diseases.
Ertapenem
go.drugbank.com/drugs/DB00303ApprovedInvestigationalErtapenem is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics.[L14339] It was first authorized for use in the US in November 2001 and in Europe in April 2002. … [A447] Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to treat various bacterial infections.
Piflufolastat F 18
go.drugbank.com/drugs/DB14805ApprovedInvestigational[L34319] The images generated by positron emission tomography (PET) are less detailed than those obtained via MRI or CT, but are more sensitive and can reveal cancerous tissue in any area of the body provided … It was first approved by the FDA in May 2021 under the brand name Pylarify and aims to allow for earlier and more accurate detection of suspected prostate cancer metastases or recurrences.
Dinoprostone
go.drugbank.com/drugs/DB00917ApprovedInvestigationalIt also stimulates osteoblasts to release factors which stimualtes bone resorption by osteoclasts. … As a prescription drug it is used as a vaginal suppository, to prepare the cervix for labour and to induce labour.
Etafedrine
go.drugbank.com/drugs/DB11587ApprovedThis belongs to the family of medications called _decongestants_. It acts by narrowing blood vessels in the nasal passages, helping to relieve nasal congestion [F6]. … It was previously available as both the free base and as the hydrochloride salt manufactured by Sanofi-Aventis (now Sanofi) has been discontinued [L2563].
Cinchocaine
go.drugbank.com/drugs/DB00527ApprovedVet approvedA local anesthetic of the amide type now generally used for surface anesthesia. … It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006)
Synonyms: 2-N-butoxy-N-(2-diethylaminoethyl)cinchoninamide, 2-butoxy-N-(2-(diethylamino)ethyl)cinchoninamideSepiapterin
go.drugbank.com/drugs/DB16326ApprovedInvestigational[L53548,L53593] Sepiapterin was granted marketing authorization by the European Commission in June 2025 and by the US FDA in July 2025 for the treatment of adults and children with phenylketonuria. … It is a natural precursor of the enzymatic co-factor tetrahydrobiopterin (BH4), which activates PAH and helps reduce blood phenylalanine levels by enhancing the conformational stability of misfolded PAH
Lusutrombopag
go.drugbank.com/drugs/DB13125ApprovedInvestigationalLusutrombopag is currently in phase III development in various European countries including Austria, Belgium, Germany, and the UK [A36730]. … Lusutrombopag was approved by the FDA on July 31st, 2018 for the same therapeutic indication under the market name Mulpleta.